The pressure is on for a new injectable glaucoma device to reach the market after developer iStar received €10m in funding to commercialise it.
The device, known as the Miniject, promotes aqueous humour outflow from the anterior chamber in glaucoma patients when injected into the eye. It follows on from iStar’s Starflo, which received its CE mark in 2012.
The Miniject is made of flexible silicone, and the bio-integration and anti-scarring properties have been upgraded from the first-generation implant.
iStar announced this week (12 April) it had received €10m at the closure of its series B equity funding round, with the money sourced from existing and new shareholders.
The iStar board of directors chairman, Michel Lussier, said the funds would complete the Miniject’s development and fund its European CE-mark clinical studies.
“Miniject offers the potential of an efficacious treatment for a disease that is a major cause of blindness globally,” he concluded.